BNTX
WAITBioNTech SE
$96.69
-2.20%delayed
News ▲ · Trend ▼ · below put trigger ▼
Expected move (1d)
▼ $92.68to$100.70 ▲
ATR ±$4.01 (+4.15%)Implied ±$4.15 (+4.29%)
Entry Reference
Price / prev close$96.69 / $98.86
Day range$95.80 – $97.66
52-wk range$79.52 – $124.00(39%)
Volume vs avg0.49×
ATR (14d)$4.01
MA 8 / 21$99.90 / $103.51
MA 50 / 200$96.88 / $97.65
Call ▲ / Put ▼ trigger$99.81 / $97.91
+1 / +2 ATR$100.70 / $104.72
-1 / -2 ATR$92.68 / $88.66
Support: 94.41 93.90 93.25
Resistance: 97.44 98.80 113.26
Near-the-money contracts
exp 2026-09-18Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 90 | $6.85 | 55% | 0.94 | -0.11 | 362 |
| 92.5 | $4.60 | 52% | 0.85 | -0.20 | 88 |
| 95 | $2.50 | 77% | 0.62 | -0.47 | 214 |
| 97.5 | $1.85 | 64% | 0.45 | -0.40 | 535 |
| 100 | $0.65 | 52% | 0.23 | -0.25 | 1357 |
| 105 | $0.15 | 60% | 0.05 | -0.10 | 1780 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 90 | $0.08 | 72% | -0.11 | -0.22 | 1113 |
| 92.5 | $0.55 | 50% | -0.14 | -0.17 | 110 |
| 95 | $0.77 | 56% | -0.34 | -0.32 | 570 |
| 97.5 | $2.30 | 53% | -0.56 | -0.32 | 1719 |
| 100 | $3.55 | 70% | -0.70 | -0.37 | 2775 |
| 105 | $8.45 | 59% | -0.95 | -0.08 | 2194 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough11h ago
- Why Is BioNTech Stock Gaining Monday?1d ago
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients2d ago
- Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat4d ago
- 10 Health Care Stocks With Whale Alerts In Today’s Session5d ago
- Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?7d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.